Drug Target Proteins: Core Tools from Target Discovery to Drug Development

Author: Senior Product Manager of UA Views：9

This article focuses on the technical characteristics and drug development applications of drug target proteins, systematically elaborating on the classification and functions of biologically active target proteins with pharmacological activity. It analyzes the druggability foundations of major drug target families such as G protein-coupled receptors, enzymes, and kinases, and explores the core role of recombinant target proteins in drug screening, structural analysis, and mechanism research.

Recent Advances
Product Information

Recent Advances

Drug Target Proteins: Core Tools from Target Discovery to Drug Development

Overview
This article systematically explores the technical characteristics and drug development applications of drug target proteins, detailing the classification and functions of biologically active target proteins. It analyzes the druggability foundations of major target families such as G protein-coupled receptors, enzymes, and kinases, and discusses the pivotal role of recombinant target proteins in drug screening, structural analysis, and mechanism research.

I. Definition and Classification of Drug Target Proteins

Biologically active "targets" generally refer to proteins that drugs directly bind to, such as enzymes, ion channels, receptors, or other biomolecules (e.g., DNA, RNA, heparin, and peptides). Most drug targets are proteins, where therapeutic or diagnostic chemicals selectively interact with target proteins, altering their biological pathways or functions.

Most drug targets belong to five protein families: G protein-coupled receptors, ion channels, kinases, nuclear hormone receptors, and proteases. G protein-coupled receptors and enzymes are the two largest classes of target proteins for drugs approved by the U.S. Food and Drug Administration. In terms of gene family distribution among human drug targets, GPCRs and enzymes account for the majority of approved drug targets, reflecting their central role in drug development.

II. Druggability Characteristics of Major Drug Target Families

G protein-coupled receptors, also known as seven-transmembrane or 7TM receptors, are the largest family of membrane receptors in humans and many other species, as well as the largest target protein family for approved drugs. Many factors contribute to the widespread use of GPCR-targeting drugs, including their druggability, interactions with various chemical entities, and expression in the plasma membrane, which facilitates molecular interactions in the extracellular environment. The critical role of GPCRs in diseases such as diabetes, obesity, Alzheimer's disease, and psychiatric disorders provides strong motivation for ongoing drug discovery and development efforts.

Enzymes are a major focus of drug discovery and development. As essential physiological catalysts in all life processes—including metabolism, cell signaling, movement, and cell growth and division—they are attractive drug targets due to their well-defined substrate-binding pockets, which can serve as binding sites for enzyme inhibitors. According to an analysis of the FDA Orange Book, there are 317 drugs that inhibit the activity of 71 enzymes, including 48 human enzymes, 13 bacterial enzymes, 5 viral enzymes, 4 fungal enzymes, and 1 protozoan enzyme. Protein kinases have now become the second most important drug target after GPCRs.

Nuclear receptors are important transcription factors that regulate gene expression in the nucleus in response to various extracellular and intracellular signals, making them ideal targets for drug discovery. Ion channels, as transmembrane proteins, control the flow of ions in and out of cells and play a central role in neural signaling, muscle contraction, and cellular homeostasis, serving as important targets for drugs targeting neurological and cardiovascular diseases.

III. The Core Role of Recombinant Target Proteins in Drug Development

Drug research aims to discover and develop new compounds that affect the function of disease-related proteins or protein-protein interactions. Having accurate functional and structural information about disease-related proteins aids drug development, as drug target proteins need to support screening, structural studies, and mechanism research, providing data to drive chemical design.

Generally, structural and protein-based drug research requires large quantities of protein. For example, crystallography studies require at least 1 mg of protein. Obtaining sufficient quantities of highly pure target protein from natural organic sources or chemical synthesis is nearly impossible. Protein libraries for drug discovery also require careful analysis of protein tertiary structures through X-ray crystallography and nuclear magnetic resonance, techniques that demand purified protein samples. Therefore, in protein structural biology research, recombinant methods capable of producing large quantities of target proteins are indispensable.

High-purity, high-activity recombinant proteins can help disease research obtain diverse qualitative and quantitative data. In drug screening and optimization, recombinant proteins can be used to test whether drugs act on potential target proteins. Additionally, recombinant proteins serve as raw materials, ensuring the quality, efficacy, and safety of biologics. Thus, recombinant proteins have become one of the essential research tools in life science studies.

IV. Applications of Recombinant Target Proteins in Drug Discovery

Recombinant target proteins have diverse applications in the drug discovery process. In virtual screening and experimental validation, researchers use recombinant target proteins for surface plasmon resonance analysis to measure the binding kinetics of candidate compounds and validate virtual screening results. In structural analysis, recombinant target proteins are core materials for X-ray crystallography and cryo-electron microscopy, providing precise molecular models for structure-based drug design. In functional validation, recombinant target proteins are used for in vitro enzyme activity assays, receptor-ligand binding analysis, and signaling pathway activation experiments. In drug screening and optimization, recombinant target proteins enable the establishment of high-throughput screening platforms to evaluate the activity and selectivity of candidate compounds.

V. Conclusion

As core tools bridging target discovery and drug development, drug target proteins play an irreplaceable role in structural analysis, functional validation, and drug screening, forming the foundational support of modern drug development systems. From the study of druggability in major target families like GPCRs and enzymes to breakthroughs in "undruggable" targets such as KRAS, recombinant target proteins consistently serve a critical function. Uni offers KRAS Avi&His Tag Protein, Human (Load GDP/GMPPNP), which includes both GDP-bound and GMPPNP (a GTP analog)-bound forms. This product can be used for binding kinetics analysis of KRAS with candidate compounds, in vitro screening of KRAS mutant-specific inhibitors, and mechanism research on KRAS signaling pathways.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next